Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

On September 16, 2017 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, reported that data from the Phase 2 trial of SL-701 in patients with second-line glioblastoma (GBM) were selected for oral presentation at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) being held November 16-19, 2017 in San Francisco, CA (Press release, Stemline Therapeutics, NOV 16, 2017, View Source [SID1234522107]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David A. Reardon, M.D., lead investigator of the study and presenting author, commented, "SL-701 is exhibiting very encouraging clinical activity, including long-term survivors, as both a single agent and in combination with bevacizumab in a relapsed GBM patient population. Notably, we are also witnessing evidence of a robust target-specific CD8+ T-cell response tracking with clinical benefit – a very exciting development and confirmation of the drug’s immune mechanism of action. Given the positive results seen here, combined with a high unmet medical need in GBM, I will be working closely with Stemline to develop a rational, registrational path forward for SL-701."

Details on the presentation are as follows:

Title:
Phase 2 Trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and survivin, in adults with second-line recurrent GBM
Presenter: David Reardon, MD; Dana-Farber Cancer Institute
Abstract: ATIM-10
Date/Time: Sunday, November 19, 2017 – 10:45-10:55 AM PT

A copy of the oral presentation will be available on the Stemline website (www.stemline.com), under the Scientific Presentations tab, following the SNO presentation.